Literature DB >> 28400483

Somatic and inherited mutations in primary aldosteronism.

Fabio Luiz Fernandes-Rosa1,2,3, Sheerazed Boulkroun1,2, Maria-Christina Zennaro1,2,3.   

Abstract

Primary aldosteronism (PA), the most common form of secondary hypertension, is caused in the majority of cases by unilateral aldosterone-producing adenoma (APA) or bilateral adrenal hyperplasia. Over the past few years, somatic mutations in KCNJ5, CACNA1D, ATP1A1 and ATP2B3 have been proven to be associated with APA development, representing more than 50% of sporadic APA. The identification of these mutations has allowed the development of a model for APA involving modification on the intracellular ionic equilibrium and regulation of cell membrane potential, leading to autonomous aldosterone overproduction. Furthermore, somatic CTNNB1 mutations have also been identified in APA, but the link between these mutations and APA development remains unknown. The sequence of events responsible for APA formation is not completely understood, in particular, whether a single hit or a double hit is responsible for both aldosterone overproduction and cell proliferation. Germline mutations identified in patients with early-onset PA have expanded the classification of familial forms (FH) of PA. The description of germline KCNJ5 and CACNA1H mutations has identified FH-III and FH-IV based on genetic findings; germline CACNA1D mutations have been identified in patients with very early-onset PA and severe neurological abnormalities. This review summarizes current knowledge on the genetic basis of PA, the association of driver gene mutations and clinical findings and in the contribution to patient care, plus the current understanding on the mechanisms of APA development.
© 2017 Society for Endocrinology.

Entities:  

Keywords:  ATPase; Wnt/β-catenin pathway; aldosterone-producing adenoma; calcium channels; familial hyperaldosteronism; germline mutations; potassium channels; primary aldosteronism; somatic mutations

Mesh:

Substances:

Year:  2017        PMID: 28400483     DOI: 10.1530/JME-17-0035

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  13 in total

Review 1.  Familial hyperaldosteronism type III a novel case and review of literature.

Authors:  Natividad Pons Fernández; Francisca Moreno; Julia Morata; Ana Moriano; Sara León; Carmen De Mingo; Ángel Zuñiga; Fernando Calvo
Journal:  Rev Endocr Metab Disord       Date:  2019-03       Impact factor: 6.514

2.  α1ACT Is Essential for Survival and Early Cerebellar Programming in a Critical Neonatal Window.

Authors:  Xiaofei Du; Cenfu Wei; Daniel Parviz Hejazi Pastor; Eshaan R Rao; Yan Li; Giorgio Grasselli; Jack Godfrey; Ann C Palmenberg; Jorge Andrade; Christian Hansel; Christopher M Gomez
Journal:  Neuron       Date:  2019-03-25       Impact factor: 17.173

3.  Mouse Models of Primary Aldosteronism: From Physiology to Pathophysiology.

Authors:  Leticia Aragao-Santiago; Celso E Gomez-Sanchez; Paolo Mulatero; Ariadni Spyroglou; Martin Reincke; Tracy Ann Williams
Journal:  Endocrinology       Date:  2017-12-01       Impact factor: 4.736

Review 4.  The Potential Role of Aldosterone-Producing Cell Clusters in Adrenal Disease.

Authors:  Jung Soo Lim; William E Rainey
Journal:  Horm Metab Res       Date:  2020-03-30       Impact factor: 2.936

Review 5.  The Biology of Normal Zona Glomerulosa and Aldosterone-Producing Adenoma: Pathological Implications.

Authors:  Teresa M Seccia; Brasilina Caroccia; Elise P Gomez-Sanchez; Celso E Gomez-Sanchez; Gian Paolo Rossi
Journal:  Endocr Rev       Date:  2018-12-01       Impact factor: 19.871

Review 6.  Progress in the Management of Primary Aldosteronism.

Authors:  Ryo Morimoto; Kei Omata; Sadayoshi Ito; Fumitoshi Satoh
Journal:  Am J Hypertens       Date:  2018-04-13       Impact factor: 2.689

7.  Pathogenesis of hypertension in a mouse model for human CLCN2 related hyperaldosteronism.

Authors:  Corinna Göppner; Ian J Orozco; Maja B Hoegg-Beiler; Audrey H Soria; Christian A Hübner; Fabio L Fernandes-Rosa; Sheerazed Boulkroun; Maria-Christina Zennaro; Thomas J Jentsch
Journal:  Nat Commun       Date:  2019-10-15       Impact factor: 14.919

8.  Circulating miRNA Expression Profiling in Primary Aldosteronism.

Authors:  Abel Decmann; Gábor Nyírö; Ottó Darvasi; Péter Turai; Irina Bancos; Ravinder Jeet Kaur; Raffaele Pezzani; Maurizio Iacobone; Ivana Kraljevic; Darko Kastelan; Mirko Parasiliti-Caprino; Mauro Maccario; Nina Nirschl; Daniel Heinrich; Martin Reincke; Attila Patócs; Peter Igaz
Journal:  Front Endocrinol (Lausanne)       Date:  2019-10-29       Impact factor: 5.555

9.  Primary Aldosteronism Decreases Insulin Secretion and Increases Insulin Clearance in Humans.

Authors:  Gail K Adler; Gillian R Murray; Adina F Turcu; Hui Nian; Chang Yu; Carmen C Solorzano; Robert Manning; Dungeng Peng; James M Luther
Journal:  Hypertension       Date:  2020-03-16       Impact factor: 10.190

10.  Phosphodiesterase 2A and 3B variants are associated with primary aldosteronism.

Authors:  Marcela Rassi-Cruz; Andrea G Maria; Fabio R Faucz; Edra London; Leticia A P Vilela; Lucas S Santana; Anna Flavia F Benedetti; Tatiana S Goldbaum; Fabio Y Tanno; Vitor Srougi; Jose L Chambo; Maria Adelaide A Pereira; Aline C B S Cavalcante; Francisco C Carnevale; Bruna Pilan; Luiz A Bortolotto; Luciano F Drager; Antonio M Lerario; Ana Claudia Latronico; Maria Candida B V Fragoso; Berenice B Mendonca; Maria Claudia N Zerbini; Constantine A Stratakis; Madson Q Almeida
Journal:  Endocr Relat Cancer       Date:  2021-01       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.